Journal of Thrombosis and Thrombolysis

, Volume 45, Issue 4, pp 529–535 | Cite as

Impact of pre-admission treatment with non-vitamin K oral anticoagulants on stroke severity in patients with acute ischemic stroke

  • Carolin Hoyer
  • Alexandra Filipov
  • Eva Neumaier-Probst
  • Kristina Szabo
  • Anne Ebert
  • Angelika Alonso
Article

Abstract

Background

Non-vitamin K antagonist oral anticoagulants (NOACs) have gained increasing importance for stroke prevention in patients with non-valvular atrial fibrillation (AF). With changing prescription practice, among other factors, clinicians can expect to see rising numbers of patients with ischemic stroke and pre-existing NOAC therapy. Few data exist regarding a potential impact of NOAC on stroke severity and outcome.

Aims

To evaluate the impact of pre-admission NOAC therapy on ischemic stroke severity.

Methods

Retrospective analysis of medical data of 376 patients with newly detected AF or known AF with either no pre-admission oral anticoagulation (n = 277) or existing NOAC therapy (n = 99; Apixaban, n = 33, Dabigatran, n = 16; Edoxaban, n = 1; Rivaroxaban, n = 49) consecutively admitted for acute ischemic stroke between January 2015 and December 2016.

Results

Patients with pre-admission NOAC had significantly more often experienced a prior stroke than patients not on NOAC therapy (45.5 vs. 18.4%, p < 0.001) and were significantly more frequently non-smokers (1.0 vs. 7.2%, p = 0.021). Significantly more patients without pre-admission NOAC received thrombolysis (33.8 vs. 8.1%, p < 0.001). Pre-admission NOAC therapy was associated with significantly lower NIHSS and mRS scores upon admission (median NIHSS score 6 vs. 10, p = 0.018, median mRS score 4 vs. 5, p = 0.035) and trend-level lower NIHSS scores at discharge (median NIHSS score 3 vs. 5, p = 0.057). There were no differences regarding the frequency of symptomatic intracerebral hemorrhage between NOAC and non-NOAC patients (p > 0.05).

Conclusions

We report a positive impact of pre-admission NOAC on ischemic stroke severity, which is particularly remarkable in light of the increased prevalence of prior stroke and lower rates of thrombolysis in this patient population.

Keywords

Atrial fibrillation NOAC Secondary prevention Neurology Ischemic stroke Stroke severity 

Notes

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

References

  1. 1.
    Hajat C, Heuschmann PU, Coshall C et al (2011) Incidence of aetiological subtypes of stroke in a multi-ethnic population based study: the South London Stroke Register. J Neurol Neurosurg Psychiatry 82:527–533.  https://doi.org/10.1136/jnnp.2010.222919 CrossRefPubMedGoogle Scholar
  2. 2.
    Dulli DA, Stanko H, Levine RL (2003) Atrial fibrillation is associated with severe acute ischemic stroke. Neuroepidemiology 22:118–123CrossRefPubMedGoogle Scholar
  3. 3.
    Holbrook AM, Pereira JA, Labiris R et al (2005) Systematic overview of warfarin and its drug and food interactions. Arch Intern Med 165:1095–1106.  https://doi.org/10.1001/archinte.165.10.1095 CrossRefPubMedGoogle Scholar
  4. 4.
    Ruff CT, Giugliano RP, Braunwald E et al (2014) Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet 383:955–962.  https://doi.org/10.1016/S0140-6736(13)62343-0 CrossRefPubMedGoogle Scholar
  5. 5.
    Bassand J-P, Accetta G, Camm AJ et al (2016) Two-year outcomes of patients with newly diagnosed atrial fibrillation: results from GARFIELD-AF. Eur Heart J 37:2882–2889.  https://doi.org/10.1093/eurheartj/ehw233 CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Loo SY, Dell’Aniello S, Huiart L, Renoux C (2017) Trends in the prescription of novel oral anticoagulants in UK primary care. Br J Clin Pharmacol 44:D1054–D2106.  https://doi.org/10.1111/bcp.13299 Google Scholar
  7. 7.
    Connolly SJ, Ezekowitz MD, Yusuf S et al (2009) Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 361:1139–1151.  https://doi.org/10.1056/NEJMoa0905561 CrossRefPubMedGoogle Scholar
  8. 8.
    Giugliano RP, Ruff CT, Braunwald E et al (2013) Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med 369:2093–2104.  https://doi.org/10.1056/NEJMoa1310907 CrossRefPubMedGoogle Scholar
  9. 9.
    Granger CB, Alexander JH, McMurray JJV et al (2011) Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 365:981–992.  https://doi.org/10.1056/NEJMoa1107039 CrossRefPubMedGoogle Scholar
  10. 10.
    Patel MR, Mahaffey KW, Garg J et al (2011) Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 365:883–891.  https://doi.org/10.1056/NEJMoa1009638 CrossRefPubMedGoogle Scholar
  11. 11.
    Zoni-Berisso M, Lercari F, Carazza T, Domenicucci S (2014) Epidemiology of atrial fibrillation: European perspective. Clin Epidemiol 6:213–220.  https://doi.org/10.2147/CLEP.S47385 CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Hart RG, Diener H-C, Connolly SJ (2014) Embolic strokes of undetermined source: support for a new clinical construct—authors’ reply. Lancet Neurol 13:967.  https://doi.org/10.1016/S1474-4422(14)70197-8 CrossRefPubMedGoogle Scholar
  13. 13.
    Hylek EM, Go AS, Chang Y et al (2003) Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation. N Engl J Med 349:1019–1026.  https://doi.org/10.1056/NEJMoa022913 CrossRefPubMedGoogle Scholar
  14. 14.
    O’Donnell M, Oczkowski W, Fang J et al (2006) Preadmission antithrombotic treatment and stroke severity in patients with atrial fibrillation and acute ischaemic stroke: an observational study. Lancet Neurol 5:749–754.  https://doi.org/10.1016/S1474-4422(06)70536-1 CrossRefPubMedGoogle Scholar
  15. 15.
    Schwammenthal Y, Bornstein N, Schwammenthal E et al (2010) Relation of effective anticoagulation in patients with atrial fibrillation to stroke severity and survival (from the National Acute Stroke Israeli Survey [NASIS]). AJC 105:411–416.  https://doi.org/10.1016/j.amjcard.2009.09.050 CrossRefGoogle Scholar
  16. 16.
    Hellwig S, Grittner U, Audebert H et al (2017) Non-vitamin K-dependent oral anticoagulants have a positive impact on ischaemic stroke severity in patients with atrial fibrillation. EP Europace.  https://doi.org/10.1093/europace/eux087 PubMedGoogle Scholar
  17. 17.
    Tomita H, Hagii J, Metoki N et al (2015) Severity and functional outcome of patients with cardioembolic stroke occurring during non-vitamin K antagonist oral anticoagulant treatment. J Stroke Cerebrovasc Dis 24:1430–1437.  https://doi.org/10.1016/j.jstrokecerebrovasdis.2015.03.004 CrossRefPubMedGoogle Scholar
  18. 18.
    Xian Y, O’Brien EC, Liang L et al (2017) Association of preceding antithrombotic treatment with acute ischemic stroke severity and in-hospital outcomes among patients with atrial fibrillation. JAMA 317:1057–1067.  https://doi.org/10.1001/jama.2017.1371 CrossRefPubMedGoogle Scholar
  19. 19.
    Hacke W, Kaste M, Fieschi C et al (1995) Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. The European Cooperative Acute Stroke Study (ECASS). JAMA 274:1017–1025CrossRefPubMedGoogle Scholar
  20. 20.
    Hacke W, Kaste M, Bluhmki E et al (2008) Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med 359:1317–1329.  https://doi.org/10.1056/NEJMoa0804656 CrossRefPubMedGoogle Scholar
  21. 21.
    Xian Y, Federspiel JJ, Hernandez AF et al (2017) Use of intravenous recombinant tissue plasminogen activator in patients with acute ischemic stroke who take non-vitamin K antagonist oral anticoagulants before StrokeClinical Perspective. Circulation 135:1024–1035.  https://doi.org/10.1161/CIRCULATIONAHA.116.023940 CrossRefPubMedGoogle Scholar
  22. 22.
    Tziomalos K, Giampatzis V, Bouziana SD et al (2015) Adequacy of preadmission oral anticoagulation with vitamin K antagonists and ischemic stroke severity and outcome in patients with atrial fibrillation. J Thromb Thrombolysis 41:336–342.  https://doi.org/10.1007/s11239-015-1262-y CrossRefGoogle Scholar
  23. 23.
    Purrucker JC, Haas K, Rizos T et al (2017) Coagulation testing in acute ischemic stroke patients taking non-vitamin K antagonist oral anticoagulants. Stroke 48:152–158.  https://doi.org/10.1161/STROKEAHA.116.014963 CrossRefPubMedGoogle Scholar
  24. 24.
    Ives SP, Heuschmann PU, Wolfe CDA, Redfern J (2008) Patterns of smoking cessation in the first 3 years after stroke: the South London Stroke Register. Eur J Cardiovasc Prev Rehabil 15:329–335.  https://doi.org/10.1097/HJR.0b013e3282f37a58 CrossRefPubMedGoogle Scholar
  25. 25.
    Micha R, Peñalvo JL, Cudhea F et al (2017) Association between dietary factors and mortality from heart disease, stroke, and type 2 diabetes in the United States. JAMA 317:912–924.  https://doi.org/10.1001/jama.2017.0947 CrossRefPubMedPubMedCentralGoogle Scholar
  26. 26.
    Rist PM, Capistrant BD, Mayeda ER et al (2017) Physical activity, but not body mass index, predicts less disability before and after stroke. Neurology 88:1718–1726.  https://doi.org/10.1212/WNL.0000000000003888 CrossRefPubMedGoogle Scholar
  27. 27.
    Wilson D, Seiffge DJ, Traenka C et al (2017) Outcome of intracerebral hemorrhage associated with different oral anticoagulants. Neurology 88:1693–1700.  https://doi.org/10.1212/WNL.0000000000003886 CrossRefPubMedPubMedCentralGoogle Scholar
  28. 28.
    Dittmeier M, Wassmuth K, Schuhmann MK et al (2016) Dabigatran etexilate reduces thrombin-induced inflammation and thrombus formation in experimental ischemic stroke. Curr Neurovasc Res 13:199–206CrossRefPubMedGoogle Scholar
  29. 29.
    Dittmeier M, Kraft P, Schuhmann MK et al (2016) Pretreatment with rivaroxaban attenuates stroke severity in rats by a dual antithrombotic and anti-inflammatory mechanism. Thromb Haemost 115:835–843.  https://doi.org/10.1160/TH15-08-0631 CrossRefPubMedGoogle Scholar
  30. 30.
    Chen T, Wang J, Li C et al (2014) Nafamostat mesilate attenuates neuronal damage in a rat model of transient focal cerebral ischemia through thrombin inhibition. Sci Rep 4:5531.  https://doi.org/10.1038/srep05531 CrossRefPubMedPubMedCentralGoogle Scholar
  31. 31.
    Wolzt M, Eriksson UG, Gouya G et al (2012) Effect on perfusion chamber thrombus size in patients with atrial fibrillation during anticoagulant treatment with oral direct thrombin inhibitors, AZD0837 or ximelagatran, or with vitamin K antagonists. Thromb Res 129:e83–e91.  https://doi.org/10.1016/j.thromres.2011.08.018 CrossRefPubMedGoogle Scholar
  32. 32.
    Wolzt M, Gouya G, Kapiotis S et al (2013) Open-label, randomized study of the effect of rivaroxaban with or without acetylsalicylic acid on thrombus formation in a perfusion chamber. Thromb Res 132:240–247.  https://doi.org/10.1016/j.thromres.2013.05.019 CrossRefPubMedGoogle Scholar
  33. 33.
    Belyaev AV, Panteleev MA, Ataullakhanov FI (2015) Threshold of microvascular occlusion: injury size defines the thrombosis scenario. Biophys J 109:450–456.  https://doi.org/10.1016/j.bpj.2015.06.019 CrossRefPubMedPubMedCentralGoogle Scholar
  34. 34.
    Jackson SP, Nesbitt WS, Westein E (2009) Dynamics of platelet thrombus formation. J Thromb Haemost 7(Suppl 1):17–20.  https://doi.org/10.1111/j.1538-7836.2009.03401.x CrossRefPubMedGoogle Scholar
  35. 35.
    Fukushima K, Fukushima N, Kato K et al (2016) Correlation between left atrial appendage morphology and flow velocity in patients with paroxysmal atrial fibrillation. Eur Heart J Cardiovasc Imaging 17:59–66.  https://doi.org/10.1093/ehjci/jev117 PubMedGoogle Scholar
  36. 36.
    Di Biase L, Santangeli P, Anselmino M et al (2012) Does the left atrial appendage morphology correlate with the risk of stroke in patients with atrial fibrillation? Results from a multicenter study. J Am Coll Cardiol 60:531–538.  https://doi.org/10.1016/j.jacc.2012.04.032 CrossRefPubMedGoogle Scholar
  37. 37.
    Demaerschalk BM, Kleindorfer DO, Adeoye OM et al (2016) Scientific rationale for the inclusion and exclusion criteria for intravenous alteplase in acute ischemic stroke. Stroke 47:581–641.  https://doi.org/10.1161/STR.0000000000000086 CrossRefPubMedGoogle Scholar
  38. 38.
    Goyal M, Menon BK, van Zwam WH et al (2016) Endovascular thrombectomy after large-vessel ischaemic stroke: a meta-analysis of individual patient data from five randomised trials. Lancet 387:1723–1731.  https://doi.org/10.1016/S0140-6736(16)00163-X CrossRefPubMedGoogle Scholar
  39. 39.
    De Marchis GM, Jung S, Colucci G et al (2011) Intracranial hemorrhage, outcome, and mortality after intra-arterial therapy for acute ischemic stroke in patients under oral anticoagulants. Stroke 42:3061–3066.  https://doi.org/10.1161/STROKEAHA.111.615476 CrossRefPubMedGoogle Scholar
  40. 40.
    Rebello LC, Haussen DC, Belagaje S et al (2015) Endovascular treatment for acute ischemic stroke in the setting of anticoagulation. Stroke 46:3536–3539.  https://doi.org/10.1161/STROKEAHA.115.011285 CrossRefPubMedGoogle Scholar
  41. 41.
    Dorn F, Prothmann S, Patzig M et al (2016) Stent retriever thrombectomy in patients who are ineligible for intravenous thrombolysis: a multicenter retrospective observational study. AJNR Am J Neuroradiol 37:305–310.  https://doi.org/10.3174/ajnr.A4520 CrossRefPubMedGoogle Scholar
  42. 42.
    Wilke T, Groth A, Pfannkuche M et al (2015) Real life anticoagulation treatment of patients with atrial fibrillation in Germany: extent and causes of anticoagulant under-use. J Thromb Thrombolysis 40:1–11.  https://doi.org/10.1007/s11239-014-1136-8 CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Department of NeurologyUniversitätsmedizin Mannheim, University of HeidelbergMannheimGermany
  2. 2.Department of NeuroradiologyUniversitätsmedizin Mannheim, University of HeidelbergMannheimGermany

Personalised recommendations